ST Renfu announced that its controlled subsidiary Yichang Renfu recently received a Drug Clinical Trial Approval Notice for Sufentanil Citrate Injection issued by the National Medical Products Administration, agreeing to conduct a clinical trial of the drug as an analgesic combined with bupivacaine for epidural administration in labor analgesia. Sufentanil is a potent opioid analgesic. Yichang Renfu's product was approved for marketing in 2005 and passed consistency evaluation in 2020. The originally approved indications are for combined anesthesia in general anesthesia and for anesthesia induction and maintenance. This application is for adding a new indication.
Humanwell Healthcare Group Co LtdSubsidiary's drug gets clinical trial approval for new indication, potentially expanding market.
